Selected article for: "high percentage and SARS spike protein"

Author: Tang, Juanjie; Ravichandran, Supriya; Lee, Youri; Grubbs, Gabrielle; Coyle, Elizabeth M.; Klenow, Laura; Genser, Hollie; Golding, Hana; Khurana, Surender
Title: Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients
  • Cord-id: pjuk5z9s
  • Document date: 2021_2_22
  • ID: pjuk5z9s
    Snippet: Hospitalized COVID-19 patients often present with a large spectrum of clinical symptoms. There is a critical need to better understand the immune responses to SARS-CoV-2 that lead to either resolution or exacerbation of the clinical disease. Here, we examine longitudinal plasma samples from hospitalized COVID-19 patients with differential clinical outcome. We perform immune-repertoire analysis including cytokine, hACE2-receptor inhibition, neutralization titers, antibody epitope repertoire, anti
    Document: Hospitalized COVID-19 patients often present with a large spectrum of clinical symptoms. There is a critical need to better understand the immune responses to SARS-CoV-2 that lead to either resolution or exacerbation of the clinical disease. Here, we examine longitudinal plasma samples from hospitalized COVID-19 patients with differential clinical outcome. We perform immune-repertoire analysis including cytokine, hACE2-receptor inhibition, neutralization titers, antibody epitope repertoire, antibody kinetics, antibody isotype and antibody affinity maturation against the SARS-CoV-2 prefusion spike protein. Fatal cases demonstrate high plasma levels of IL-6, IL-8, TNFα, and MCP-1, and sustained high percentage of IgA-binding antibodies to prefusion spike compared with non-ICU survivors. Disease resolution in non-ICU and ICU patients associates with antibody binding to the receptor binding motif and fusion peptide, and antibody affinity maturation to SARS-CoV-2 prefusion spike protein. Here, we provide insight into the immune parameters associated with clinical disease severity and disease-resolution outcome in hospitalized patients that could inform development of vaccine/therapeutics against COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and adaptive immune response failure: 1
    • acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and adaptive innate immunity: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and longitudinal analysis: 1, 2
    • acute ards respiratory distress syndrome and longitudinal study: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome develop and adaptive immune response: 1
    • acute ards respiratory distress syndrome develop and adaptive innate: 1, 2
    • acute ards respiratory distress syndrome develop and adaptive innate immunity: 1
    • acute ards respiratory distress syndrome develop and admission day: 1
    • acute infection and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and adaptive immune response failure: 1
    • acute infection and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and adaptive innate immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute infection and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and longitudinal analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute infection and longitudinal antibody: 1, 2, 3, 4, 5, 6, 7
    • acute infection and longitudinal antibody analysis: 1, 2
    • adaptive immune response and longitudinal analysis: 1, 2